One of the largest studies ever conducted on prenatal medication exposure has found that children whose mothers filled opioid prescriptions during pregnancy face a measurably higher risk of being hospitalized in childhood, with the effect persisting for up to five years after birth. The research, published in PLOS Medicine, drew on the health records of more than 2.9 million children born in South Korea between 2010 and 2017, making it an order of magnitude larger than most previous investigations into the long-term consequences of fetal opioid exposure. The findings arrive at a moment when clinicians worldwide are still wrestling with how to balance legitimate pain relief for pregnant women against the possibility of subtle, lasting harm to the developing child.
The study team, led by Hyeon Jin Kim and Dong Keon Yon, constructed a population-based birth cohort by linking mothers to their children through South Korea’s National Health Insurance Service database, following families from January 2009 through December 2023. Because the insurance system covers virtually the entire population, the dataset captures an extraordinarily complete picture of medical care. In total, the cohort encompassed 2,236,167 mothers and 3,013,262 children, with individual children followed for as long as 14 years depending on their birth year. Prenatal opioid exposure was defined conservatively: a mother had to have received at least two opioid prescriptions within a single trimester of pregnancy to count as exposed.
Among the 2,928,186 children included in the primary analysis, 118,671 had documented prenatal opioid exposure while 2,809,515 did not. Roughly half of each group was male, and the researchers adjusted their statistical models for an unusually thorough list of potential confounders, including maternal age at delivery, infant sex, region of residence, household income, birth season, parity, a severe maternal morbidity score, the number of outpatient visits and hospital admissions in the year before pregnancy, preterm birth, low birth weight, delivery type, year of delivery, plurality, and maternal histories of substance use and neuropsychiatric disorders. This level of adjustment matters, because mothers who receive opioids during pregnancy differ from those who do not in many ways that could independently affect their children’s health.
The headline result was stark. In the propensity score-matched cohort, where exposed and unexposed children were balanced on dozens of measured characteristics, children with prenatal opioid exposure were hospitalized at rates 28 percent higher than their unexposed peers, with an adjusted incidence rate ratio of 1.28 and a confidence interval of 1.28 to 1.29. In absolute terms, that difference translates into a substantial number of additional hospital admissions across a population of this size, spanning everything from chest infections to broken arms. The sheer scale of the cohort gives the estimate unusual precision, and the association held after every adjustment the researchers applied.
What elevates the study above many of its predecessors is its use of sibling comparisons, a design that partially controls for the stable genetic and environmental factors shared by brothers and sisters. When the researchers compared siblings discordant for prenatal opioid exposure, essentially asking whether a child exposed in utero was hospitalized more often than a sibling from the same mother who was not exposed, the association shrank considerably, from a 28 percent excess to an 8 percent excess. Crucially, however, it did not disappear. The attenuated estimate, with a rate ratio of 1.08, remained statistically significant, suggesting that shared familial factors explain part but not all of the observed link.
The dose-response pattern added further weight to the findings. Children whose mothers received low cumulative opioid doses showed a 19 percent higher hospital admission rate, while those whose mothers received high doses showed a 40 percent higher rate. A similar gradient emerged with the duration of prescriptions. In epidemiology, a dose-dependent relationship is often taken as evidence that an association is not merely an artifact of confounding, since confounders rarely track so neatly with the exposure of interest. The researchers also found that the association weakened as children aged but remained detectable through age five, hinting at a biological effect that fades over time rather than a permanent vulnerability.
Perhaps the most striking aspect of the results is their breadth. Prenatal opioid exposure was associated with increased hospital admission rates across multiple distinct categories of illness: infections, non-infectious respiratory conditions, non-infectious gastrointestinal conditions, oral cavity diseases, injuries and external causes, and non-infectious genitourinary conditions. A pattern this diffuse does not point to a single damaged organ system. Instead, it is consistent with the hypothesis, advanced in earlier experimental work, that prenatal opioid exposure may disrupt the development of the infant immune system, leaving children broadly more susceptible to the ordinary illnesses and accidents of early childhood rather than to any one specific disease.
The biological plausibility of such a mechanism rests on well-established pharmacology. Opioids cross the placenta, and fetal brain tissue is rich in opioid receptors from early in gestation. Animal studies have shown that prenatal opioid exposure can alter immune cell development, inflammatory signaling, and stress-response systems, any of which could plausibly influence a child’s resilience to infection or recovery from illness. Human studies of neonatal opioid withdrawal syndrome have long documented immediate effects on newborns, but evidence about consequences that emerge months or years later has been sparse and often confounded by the social circumstances that accompany opioid use. A cohort of nearly three million children offers a rare opportunity to separate signal from noise.
The authors are careful about the limits of their data. Prescription records show what pharmacies dispensed, not what pregnant women actually ingested, and adherence may differ between those who fill multiple prescriptions and those who do not. Residual confounding also cannot be excluded: no statistical model can fully account for unmeasured differences in health, pain conditions, or family circumstances between women who receive opioids during pregnancy and those who do not. The sibling analysis partially addresses this concern, but siblings share only some of the relevant environment, and the attenuation observed in that analysis is itself a reminder that much of the raw association may reflect familial background rather than the drug itself.
Even with those caveats, the study’s practical implications are relatively clear. The authors suggest that the findings could inform postnatal monitoring and management strategies for children born to mothers who received opioid prescriptions during pregnancy, potentially flagging these children for closer follow-up in the vulnerable early years when the excess risk is most pronounced. The results do not argue that opioids should be withheld from pregnant women in severe pain, a decision that belongs to patients and their clinicians weighing individual circumstances. What they do provide is a population-level evidence base for a question that has grown urgent as opioid prescribing has expanded globally: that fetal exposure to these medications may leave a measurable, if modest and fading, imprint on childhood health that deserves attention from both researchers and pediatricians.
Subject of Research: The association between prenatal opioid exposure and childhood hospital admission risk
Article Title: Maternal opioid prescriptions and subsequent risk of hospital admission in offspring in South Korea: A nationwide birth cohort study
Article References: Kim, H. J., Yim, Y., Nehs, C. J., Park, J., Kim, E. S., Cho, S. J., Fond, G., Boyer, L., Kang, J., & Yon, D. K. (2026). Maternal opioid prescriptions and subsequent risk of hospital admission in offspring in South Korea: A nationwide birth cohort study. PLOS Medicine, 23(10), e1004829. https://doi.org/10.1371/journal.pmed.1004829
Image Credits: AI Generated
DOI: 10.1371/journal.pmed.1004829
Keywords: prenatal opioid exposure, birth cohort, hospital admissions, South Korea, National Health Insurance Service, propensity score matching, sibling comparison, dose-response, immune system development, pediatric health, pharmacoepidemiology, PLOS Medicine
News Source: Harold Sullivan. (October 13, 2026). Opioid Prescriptions in Pregnancy Linked to Higher Hospital Admission Risk in Children. Scienmag.
